IFNα-derived AcTaferon-targeting melanoma displayed more potent antitumor activity (>1,000-fold) compared to wild-type IFNα. Combined with anti-PD-L1 Ab blockade complete tumour regression was observed without toxicity. Here, IFNA2 is linked to neoplasm.